Issue of Equity
CRISM Therapeutics Corporation has announced the issue of 472,222 new ordinary shares at 9 pence per share to a consultant, with admission expected on or around October 20, 2026. Following this issuance, the Company's total issued share capital will be 79,657,488 ordinary shares, representing the total number of voting rights.
Select text to share a quote on X · sign in to keep highlights & notes in your CRTX notes
CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announces it has entered into a subscription agreement, pursuant to which it will issue 472,222 new ordinary shares of no par value each in the Company (the “New Ordinary Shares") at a price of 9 pence per share, to a consultant.
Admission and Total Voting Rights
Application has been made to the London Stock Exchange for admission of the New Ordinary Shares ("Admission"). It is expected that Admission will become effective and that trading will commence in the New Ordinary Shares at 8.00 a.m. on or around 20 October 2026. The New Ordinary Shares will rank pari passu with the Company's existing ordinary shares of no par value (“Ordinary Shares”).
Following the issue of the New Ordinary Shares, the total issued share capital of the Company will consist of 79,657,488 Ordinary Shares. The Company does not hold any ordinary shares in treasury. Therefore, the total number of voting rights in the Company will be 79,657,488 and this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
The Company's LEI is 213800XFW6MKVCHHPW88.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.